celecoxib has been researched along with Lymphoma, B-Cell, Marginal Zone in 1 studies
Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, M | 1 |
| Takahashi, T | 1 |
| Matsui, H | 1 |
| Takahashi, S | 1 |
| Murayama, SY | 1 |
| Suzuki, H | 1 |
| Tsuchimoto, K | 1 |
1 other study available for celecoxib and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models | 2014 |